132 related articles for article (PubMed ID: 33234054)
1. Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors.
Lorusso L; Romei C; Piaggi P; Fustini C; Molinaro E; Agate L; Bottici V; Viola D; Pellegrini G; Elisei R
Thyroid; 2021 Jul; 31(7):1050-1055. PubMed ID: 33234054
[No Abstract] [Full Text] [Related]
2. Serum Thyroglobulin Doubling Time in Progressive Thyroid Cancer.
Rössing RM; Jentzen W; Nagarajah J; Bockisch A; Görges R
Thyroid; 2016 Dec; 26(12):1712-1718. PubMed ID: 27750024
[TBL] [Abstract][Full Text] [Related]
3. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.
Laure Giraudet A; Al Ghulzan A; Aupérin A; Leboulleux S; Chehboun A; Troalen F; Dromain C; Lumbroso J; Baudin E; Schlumberger M
Eur J Endocrinol; 2008 Feb; 158(2):239-46. PubMed ID: 18230832
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
Barbet J; Campion L; Kraeber-Bodéré F; Chatal JF;
J Clin Endocrinol Metab; 2005 Nov; 90(11):6077-84. PubMed ID: 16091497
[TBL] [Abstract][Full Text] [Related]
5. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy.
Hajje G; Borget I; Leboulleux S; Chougnet C; Al Ghuzlan A; Mirghani H; Caramella C; Hartl D; Schlumberger M; Baudin E
Eur J Endocrinol; 2013 Feb; 168(2):113-8. PubMed ID: 23093698
[TBL] [Abstract][Full Text] [Related]
6. Calcitonin doubling time in medullary thyroid carcinoma after the detection of distant metastases keenly predicts patients' carcinoma death.
Ito Y; Miyauchi A; Kihara M; Kudo T; Miya A
Endocr J; 2016 Jul; 63(7):663-7. PubMed ID: 27097545
[TBL] [Abstract][Full Text] [Related]
7. Estimating the Growth Rate of Lung Metastases in Differentiated Thyroid Carcinoma: Response Evaluation Criteria in Solid Tumors or Doubling Time?
Song E; Ahn J; Jeon MJ; Lee SM; Lee JH; Kim TY; Baek JH; Kim WB; Shong YK; Kim WG
Thyroid; 2020 Mar; 30(3):418-424. PubMed ID: 31880976
[No Abstract] [Full Text] [Related]
8. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.
Tocchi A; Costa G; Lepre L; Liotta G; Mazzoni G; Cianetti A; Vannini P
J Cancer Res Clin Oncol; 1998; 124(8):450-5. PubMed ID: 9750022
[TBL] [Abstract][Full Text] [Related]
9. Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases.
Yang XQ; Chen C; Peng CW; Liu SP; Li Y
Med Oncol; 2012 Jun; 29(2):1030-6. PubMed ID: 21553105
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous Deceleration and Acceleration of Growth Rate in Medullary Thyroid Carcinomas Suggested by Changes in Calcitonin Doubling Times Over Long-Term Surveillance.
Miyauchi A; Kudo T; Kihara M; Oda H; Ito Y; Miya A
World J Surg; 2019 Feb; 43(2):504-512. PubMed ID: 30229381
[TBL] [Abstract][Full Text] [Related]
11. Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer.
Elisei R; Lorusso L; Piaggi P; Torregrossa L; Pellegrini G; Molinaro E; Agate L; Bottici V; Pani F; Cacciato Insilla A; Casella F; Ciampi R; Tognetti I; Materazzi G; Basolo F; Romei C
Eur J Endocrinol; 2015 Sep; 173(3):297-304. PubMed ID: 26034076
[TBL] [Abstract][Full Text] [Related]
12. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor subtype 1 might be a predictor of better response to therapy in medullary thyroid carcinoma.
Kendler DB; Araújo ML; Alencar R; de Souza Accioly MT; Bulzico DA; de Noronha Pessoa CC; Accioly FA; de Farias TP; Lopes FPPL; Corbo R; Vaisman M; Vaisman F
Endocrine; 2017 Dec; 58(3):474-480. PubMed ID: 28948577
[TBL] [Abstract][Full Text] [Related]
14. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
[TBL] [Abstract][Full Text] [Related]
15. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma.
Kouri M; Pyrhönen S; Kuusela P
J Surg Oncol; 1992 Feb; 49(2):78-85. PubMed ID: 1738240
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
17. Medullary thyroid carcinoma surgical cytoreduction induces an increase in serum calcitonin and carcinoembryonic antigen doubling times.
Papapetrou PD; Polymeris A
Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):164-8. PubMed ID: 22328112
[TBL] [Abstract][Full Text] [Related]
18. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
20. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
